Han Weidong相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling

DUSP6 消融可通过增强 AP-1 信号传导来恢复因肿瘤 CD58 丢失而受损的 CAR T 细胞活性。

期刊:Signal Transduction and Targeted Therapy

影响因子:52.7

doi:10.1038/s41392-026-02597-5

Ma, Xinran; Zhang, Yang; Wang, Yao; Han, Fuxin; Lu, Yuting; Tong, Chuan; Guo, Yelei; Wei, Jianshu; Zhu, Qi; Dong, Liang; Cao, Zhi; Meng, Zhenzhen; Shi, Jinhong; Wu, Zhiqiang; Han, Weidong

细胞生物学

发表日期：2026

文献求助收藏

Reduced YTHDF2 inhibits PD-L1 expression by stabilizing m(6)A-containing SPOP mRNA in colorectal cancer.

结直肠癌中 YTHDF2 的减少通过稳定含有 m(6)A 的 SPOP mRNA 来抑制 PD-L1 的表达。

期刊:Cell Death & Disease

影响因子:9.6

doi:10.1038/s41419-026-08615-2

Xu Xian, Chen Hao, Zhao Rongjie, Xie Jiansheng, Liu Hao, Xie Binbin, Lou Jun, Wang Haidong, Wu Xinkai, Han Weidong, Pan Hongming, Shen Jiaying

发表日期：2026

文献求助收藏

Antitumor effects of STING agonists on nervous system tumors via tumor-intrinsic STING-STAT1-mediated HMGN2 expression.

STING激动剂通过肿瘤内在的STING-STAT1介导的HMGN2表达对神经系统肿瘤产生抗肿瘤作用。

期刊:Cancer Biology & Medicine

影响因子:8.4

doi:10.20892/j.issn.2095-3941.2025.0326

Lv Zijian, Wang Tiance, Fan Runjia, Ming Qianyi, Liu Jiejie, Jia Yulin, Zhang Yan, Chen Meixia, Chen Wei, Jiang Zhengfan, Han Weidong, Mei Qian

发表日期：2026

文献求助收藏

CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.

CD52 通过巨噬细胞 Siglec-G 发出信号，是癌症免疫疗法的治疗靶点。

期刊:NPJ Breast Cancer

影响因子:7.6

doi:10.1038/s41523-026-00895-3

Qin Xueting, Chang Yixin, Qiu Yuanyuan, Han Weidong, Nie Jing

细胞生物学

免疫/内分泌

发表日期：2026

文献求助收藏

A compass in the challenge: the CALLY index as a prognostic biomarker in advanced cholangiocarcinoma treated with chemoimmunotherapy: a retrospective propensity score-matched cohort study

挑战中的指南针：CALLY 指数作为接受化疗免疫疗法治疗的晚期胆管癌的预后生物标志物：一项回顾性倾向评分匹配队列研究

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2026.1713495

Fan, Runjia; Lv, Zijian; Wang, Tiance; Chen, Wei; Han, Weidong; Mei, Qian

免疫/内分泌

发表日期：2026

文献求助收藏

CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation

CD2增强通过免疫突触重塑和减轻T细胞耗竭来提高CAR-T细胞的疗效

期刊:Cellular & Molecular Immunology

影响因子:19.8

doi:10.1038/s41423-025-01314-6

Zhu, Qi; Li, Jiajia; Liu, Nan; Han, Lu; Wu, Zhiqiang; Wang, Yao; Lin, Xin; Wei, Jianshu; Han, Weidong

细胞生物学

免疫/内分泌

发表日期：2025

文献求助收藏

Platelet-to-Neutrophil Ratio: A Novel Prognostic Indicator for Anti-PD-1-Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors

血小板与中性粒细胞比值：复发/难治性霍奇金淋巴瘤和实体瘤抗PD-1疗法的新型预后指标

影响因子:10.7

doi:10.1002/mco2.70199

Pan, Yuting; Zhang, Xin; Wang, Chunmeng; Lu, Nannan; Liu, Yang; Chang, Yixin; Qin, Xueting; Han, Weidong; Nie, Jing

中性粒细胞

细胞生物学

发表日期：2025

文献求助收藏

Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma

中国专家就CAR-T细胞疗法治疗淋巴瘤的多学科团队综合病例管理达成共识

期刊:Chinese Medical Journal

影响因子:7.3

doi:10.1097/CM9.0000000000003085

Tu, Sanfang; Li, Ping; Mei, Heng; Liu, Yang; Hu, Yongxian; Liu, Peng; Zou, Dehui; Niu, Ting; Xu, Kailin; Wang, Li; Yang, Jianmin; Zhao, Mingfeng; Huang, Xiaojun; Wang, Jianxiang; Hu, Yu; Zhao, Weili; Wu, Depei; Ma, Jun; Qian, Wenbin; Han, Weidong; Li, Yuhua; Liang, Aibin

细胞生物学

免疫/内分泌

发表日期：2025

文献求助收藏

Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review

信迪利单抗联合化疗治疗原发性肺绒毛膜癌男性患者：病例报告及文献综述

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2025.1523316

Liang, Xiaojing; Xu, Guoqing; Zhang, Jisong; Xu, Li; Dong, Liangliang; Wang, Xiaoyue; Han, Weidong; Chen, Enguo

发表日期：2025

文献求助收藏

Synthesis, function, and therapeutic potential of glycosphingolipids

糖鞘脂的合成、功能和治疗潜力

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2025.1673713

Dong, Liang; Cao, Zhi; Han, Weidong; Wu, Zhiqiang

发表日期：2025

文献求助收藏